Tarek Meniawy

Tarek Meniawy serves as a Clinical Associate Professor at the UWA Medical School, University of Western Australia, specializing in Internal Medicine with a focus on oncology. He maintains active clinical appointments at multiple major healthcare institutions across Western Australia.

Dr. Meniawy earned his PhD in Immunological Biomarkers of Outcome in Thoracic Cancers from The University of Western Australia (awarded April 26, 2016) and completed his medical degree (MBBS) at Cairo University (awarded October 1, 2000).

His research expertise spans Gynaecological Cancers, Melanoma, Clinical Trials, Tumour Immunology, and Immunotherapy. His scholarly fingerprint reveals substantial contributions to Melanoma (100%), Ovarian Cancer (52%), Circulating Tumor DNA (52%), Metastatic Melanoma (40%), Solid Malignant Neoplasm (37%), Nivolumab (37%), Krukenberg Tumor (34%), and Circulating Tumor Cell (33%) research.

Dr. Meniawy's recent publications demonstrate his leadership in gynecological oncology and melanoma research, with studies examining homologous recombination deficiency testing, telehealth applications in cancer care, sarcopenia assessment in ovarian cancer patients, and novel therapeutic approaches for endometrial cancer.

• PARAGON-II: Phase 2 basket study of an Aromatase inhibitor plus PI3KCA inhibitor or CDK4/6 inhibitor in women with hormone receptor positive recurrent/metastatic Gynaecological Neoplasms (Medical Research Future Fund MRFF, 2020-2023)
• Suzanne Cavanagh ECI Grant - Immunological biomarkers in peripheral blood as a predictor of response to immunotherapy (Cancer Council NSW, 2016)
• Suzanne Cavanagh ECI Grant - Immunological biomarkers in patients with advanced ovarian cancer treated with schematic chemotherapy (Cancer Council NSW, 2015)

With 116 research outputs including 53 articles and 47 abstracts, Dr. Meniawy's work has accumulated 2,598 citations and an h-index of 27. He actively collaborates with researchers across multiple institutions and contributes to high-impact clinical trials in melanoma and gynecological cancers.